董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Laurie B. Keating | 女 | Director | 69 | 10.68万美元 | 20.48 | 2023-05-01 |
| Peter Feinberg | 男 | Director | 63 | 10.34万美元 | 140.30 | 2023-05-01 |
| Benjamin J. Zeskind | 男 | Co-Founder, President, Chief Executive Officer, Director | 41 | 166.06万美元 | 449.91 | 2023-05-01 |
| Diana F. Hausman | 女 | Director | 60 | 10.15万美元 | 12.11 | 2023-05-01 |
| Robert J. Carpenter | 男 | Chairman and Director | 78 | 9.35万美元 | 135.84 | 2023-05-01 |
| Ann E. Berman | 女 | Director | 71 | 5.55万美元 | 未持股 | 2023-05-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Benjamin J. Zeskind | 男 | Co-Founder, President, Chief Executive Officer, Director | 41 | 166.06万美元 | 449.91 | 2023-05-01 |
| Scott Barrett | 男 | Chief Medical Officer | 60 | 107.80万美元 | 未持股 | 2023-05-01 |
| Brett Hall | 男 | Chief Scientific Officer | 55 | 128.95万美元 | 128.68 | 2023-05-01 |
| Michael D. Bookman | 男 | Chief Legal Officer, Secretary | 36 | 89.04万美元 | 38.89 | 2023-05-01 |
| Harold E. Brakewood | 男 | Chief Business Officer | 58 | 未披露 | 未持股 | 2023-05-01 |
| Mallory Morales | 女 | Vice President, Finance and Treasurer | 39 | 未披露 | 未持股 | 2023-05-01 |
| Leah R. Neufeld | 女 | Chief People Officer | 51 | 未披露 | 未持股 | 2023-05-01 |
董事简历
中英对照 | 中文 | 英文- Laurie B. Keating
-
Laurie B. Keating，2014年9月以来，她担任Immuneering Corporation的高级副总裁、法律总顾问、秘书。加入Alnylam之前，她曾担任Millennium的高级副总裁、总法律顾问兼秘书。从2004年9月到2014年1月，The Takeda Oncology Company是一个生物制药公司。Millennium之前，她曾是Hydra Biosciences, Inc.的联合创始人和第一首席执行官。创办Hydra之前，她担任几个高增长科技公司的执行官。从法律学院毕业时，她在McCutchen, Doyle, Brown and Enersen（成为ingham McCutchen，现在是Morgan, Lewis & Bockius的一部分）进行法律实践。
Laurie B. Keating,has served on Immuneering Corporation Board of Directors since March 2021. Ms. Keating previously served as the Executive Vice President, Chief Legal Officer and Secretary of Alnylam Pharmaceuticals, Inc., from March 2019 until September 2021, and also served as its Senior Vice President, General Counsel and Secretary from September 2014 until March 2019. From September 2004 until January 2014, she served as the Senior Vice President, General Counsel and Secretary of Millennium Pharmaceuticals, Inc., a wholly owned oncology-focused subsidiary of Takeda Pharmaceutical Company Limited since 2008, and was the founding Chief Executive Officer and a member of the board of directors of Hydra Biosciences. Ms. Keating currently chairs the board of directors of a clinical-stage biopharmaceutical company, PepGen Inc. (Nasdaq:PEPG), where she also chairs the Compensation Committee and is a member of the Audit and Nominating and Corporate Governance committees. From November 2021 until the company was acquired by Merck in January 2023, she served on the board of directors of Imago BioSciences (Nasdaq:IMGO), and from 2005 until March 2022 she served on the board of directors of MassBIO, a non-profit organization. Ms. Keating earned her A.B. in economics from the University of California, Berkeley and her J.D. from the University of California, Hastings College of the Law. - Laurie B. Keating，2014年9月以来，她担任Immuneering Corporation的高级副总裁、法律总顾问、秘书。加入Alnylam之前，她曾担任Millennium的高级副总裁、总法律顾问兼秘书。从2004年9月到2014年1月，The Takeda Oncology Company是一个生物制药公司。Millennium之前，她曾是Hydra Biosciences, Inc.的联合创始人和第一首席执行官。创办Hydra之前，她担任几个高增长科技公司的执行官。从法律学院毕业时，她在McCutchen, Doyle, Brown and Enersen（成为ingham McCutchen，现在是Morgan, Lewis & Bockius的一部分）进行法律实践。
- Laurie B. Keating,has served on Immuneering Corporation Board of Directors since March 2021. Ms. Keating previously served as the Executive Vice President, Chief Legal Officer and Secretary of Alnylam Pharmaceuticals, Inc., from March 2019 until September 2021, and also served as its Senior Vice President, General Counsel and Secretary from September 2014 until March 2019. From September 2004 until January 2014, she served as the Senior Vice President, General Counsel and Secretary of Millennium Pharmaceuticals, Inc., a wholly owned oncology-focused subsidiary of Takeda Pharmaceutical Company Limited since 2008, and was the founding Chief Executive Officer and a member of the board of directors of Hydra Biosciences. Ms. Keating currently chairs the board of directors of a clinical-stage biopharmaceutical company, PepGen Inc. (Nasdaq:PEPG), where she also chairs the Compensation Committee and is a member of the Audit and Nominating and Corporate Governance committees. From November 2021 until the company was acquired by Merck in January 2023, she served on the board of directors of Imago BioSciences (Nasdaq:IMGO), and from 2005 until March 2022 she served on the board of directors of MassBIO, a non-profit organization. Ms. Keating earned her A.B. in economics from the University of California, Berkeley and her J.D. from the University of California, Hastings College of the Law.
- Peter Feinberg
-
Peter Feinberg自2021年1月以来一直在我们的董事会任职。Feinberg先生目前还担任Boxcar Partners（一家专注于生物技术投资的风险投资公司）的合伙人和创始成员，以及Sporos BioVentures，Inc.的创始人。此外，他目前担任BridgeBioPharma，Inc.（上市生物技术公司，专注于基因疾病、Boxcar PMJ LP和新兴安全解决方案）的联合创始人。他在奥本海默公司（Oppenheimer&Co.）拥有超过30年的金融服务行业经验。Inc.，他曾担任董事总经理。费恩伯格先生在惠蒂尔学院获得了金融学士学位。
Peter Feinberg,has served on Immuneering Corporation Board of Directors since January 2021. Mr. Feinberg also currently serves as Partner and was a Founding Member of Boxcar Partners, a venture capital investment firm with a focus on biotechnology investing, and Founder of Sporos Bioventures, Inc. In addition, he currently serves as Co-Founder of BridgeBio Pharma, Inc., a publicly traded biotechnology company focusing on genetic diseases, Boxcar PMJ LP and Emerging Security Solutions. He has more than three decades of experience in the financial services industry at Oppenheimer & Co. Inc. where he served as a Managing Director. Mr. Feinberg received his B.S. in finance from Whittier College. - Peter Feinberg自2021年1月以来一直在我们的董事会任职。Feinberg先生目前还担任Boxcar Partners（一家专注于生物技术投资的风险投资公司）的合伙人和创始成员，以及Sporos BioVentures，Inc.的创始人。此外，他目前担任BridgeBioPharma，Inc.（上市生物技术公司，专注于基因疾病、Boxcar PMJ LP和新兴安全解决方案）的联合创始人。他在奥本海默公司（Oppenheimer&Co.）拥有超过30年的金融服务行业经验。Inc.，他曾担任董事总经理。费恩伯格先生在惠蒂尔学院获得了金融学士学位。
- Peter Feinberg,has served on Immuneering Corporation Board of Directors since January 2021. Mr. Feinberg also currently serves as Partner and was a Founding Member of Boxcar Partners, a venture capital investment firm with a focus on biotechnology investing, and Founder of Sporos Bioventures, Inc. In addition, he currently serves as Co-Founder of BridgeBio Pharma, Inc., a publicly traded biotechnology company focusing on genetic diseases, Boxcar PMJ LP and Emerging Security Solutions. He has more than three decades of experience in the financial services industry at Oppenheimer & Co. Inc. where he served as a Managing Director. Mr. Feinberg received his B.S. in finance from Whittier College.
- Benjamin J. Zeskind
-
Benjamin J.Zeskind自2008年2月起担任我们的联合创始人、总裁、首席执行官和董事会成员。泽斯金德博士在麻省理工学院（MIT）获得电气工程和计算机科学学士学位，生物工程博士学位，在哈佛商学院（Harvard Business School）获得工商管理硕士学位，在那里他被公认为贝克学者，这是最高荣誉奖项。
Benjamin J. Zeskind,has served as Immuneering Corporation Co-Founder, President, Chief Executive Officer and a member of Immuneering Corporation Board of Directors since February 2008. Dr. Zeskind received his S.B. in electrical engineering and computer science and his Ph.D. in bioengineering from Massachusetts Institute of Technology, or MIT, and his M.B.A. from Harvard Business School, where he was recognized as a Baker Scholar, the highest award for distinction. - Benjamin J.Zeskind自2008年2月起担任我们的联合创始人、总裁、首席执行官和董事会成员。泽斯金德博士在麻省理工学院（MIT）获得电气工程和计算机科学学士学位，生物工程博士学位，在哈佛商学院（Harvard Business School）获得工商管理硕士学位，在那里他被公认为贝克学者，这是最高荣誉奖项。
- Benjamin J. Zeskind,has served as Immuneering Corporation Co-Founder, President, Chief Executive Officer and a member of Immuneering Corporation Board of Directors since February 2008. Dr. Zeskind received his S.B. in electrical engineering and computer science and his Ph.D. in bioengineering from Massachusetts Institute of Technology, or MIT, and his M.B.A. from Harvard Business School, where he was recognized as a Baker Scholar, the highest award for distinction.
- Diana F. Hausman
-
Diana F. Hausman，自2022年1月起在Immuneering Corporation董事会任职。Hausman博士是Link Immunotherapeutics的首席医疗官，她自2022年3月起担任该职位。2021年6月至2022年3月，Hausman博士担任蓝图医药公司全资子公司Lengo Therapeutics的首席医疗官。在加入Lengo之前，Hausman博士于2016年6月至2021年5月担任Zymeworks Inc.的首席医疗官，并于2009年至2016年担任Oncothyreon Inc.的首席医疗官。她还在ZymoGenetics Inc.、Berlex Inc.和Immunex Corporation担任越来越重要的职务，从事多个适应症的工作，包括肿瘤学、血液学、丙型肝炎和自身免疫性疾病。Hausman博士在华盛顿州西雅图的华盛顿大学接受了血液学和医学肿瘤学的内科和专业培训。她在宾夕法尼亚大学获得医学博士学位，并在普林斯顿大学获得生物学学士学位。
Diana F. Hausman,has served on Immuneering Corporation Board of Directors since January 2022. Dr. Hausman is the Chief Medical Officer of Link Immunotherapeutics, a position she has held since March 2022. From June 2021 to March 2022, Dr. Hausman served as the Chief Medical Officer of Lengo Therapeutics, a wholly-owned subsidiary of Blueprint Medicines Corporation. Prior to Lengo, Dr. Hausman served as Chief Medical Officer for Zymeworks Inc. from June 2016 to May 2021 and as Chief Medical Officer for Oncothyreon Inc from 2009 to 2016. She also held positions of increasing responsibility at ZymoGenetics Inc., Berlex Inc., and Immunex Corporation, working across multiple indications, including oncology, hematology, hepatitis C and autoimmune disease. Dr. Hausman received her internal medicine and specialty training in hematology and medical oncology at the University of Washington, Seattle, WA. She received her MD degree from the University of Pennsylvania and an A.B in biology from Princeton University. - Diana F. Hausman，自2022年1月起在Immuneering Corporation董事会任职。Hausman博士是Link Immunotherapeutics的首席医疗官，她自2022年3月起担任该职位。2021年6月至2022年3月，Hausman博士担任蓝图医药公司全资子公司Lengo Therapeutics的首席医疗官。在加入Lengo之前，Hausman博士于2016年6月至2021年5月担任Zymeworks Inc.的首席医疗官，并于2009年至2016年担任Oncothyreon Inc.的首席医疗官。她还在ZymoGenetics Inc.、Berlex Inc.和Immunex Corporation担任越来越重要的职务，从事多个适应症的工作，包括肿瘤学、血液学、丙型肝炎和自身免疫性疾病。Hausman博士在华盛顿州西雅图的华盛顿大学接受了血液学和医学肿瘤学的内科和专业培训。她在宾夕法尼亚大学获得医学博士学位，并在普林斯顿大学获得生物学学士学位。
- Diana F. Hausman,has served on Immuneering Corporation Board of Directors since January 2022. Dr. Hausman is the Chief Medical Officer of Link Immunotherapeutics, a position she has held since March 2022. From June 2021 to March 2022, Dr. Hausman served as the Chief Medical Officer of Lengo Therapeutics, a wholly-owned subsidiary of Blueprint Medicines Corporation. Prior to Lengo, Dr. Hausman served as Chief Medical Officer for Zymeworks Inc. from June 2016 to May 2021 and as Chief Medical Officer for Oncothyreon Inc from 2009 to 2016. She also held positions of increasing responsibility at ZymoGenetics Inc., Berlex Inc., and Immunex Corporation, working across multiple indications, including oncology, hematology, hepatitis C and autoimmune disease. Dr. Hausman received her internal medicine and specialty training in hematology and medical oncology at the University of Washington, Seattle, WA. She received her MD degree from the University of Pennsylvania and an A.B in biology from Princeton University.
- Robert J. Carpenter
-
RobertJ.Carpenter Carpenter先生是Boston Medical Investors，Inc.的总裁。Boston Medical Investors，Inc.是他于1994年成立的一家私人控股公司，投资于早期医疗保健公司。Carpenter从2002年1月到2007年8月担任Peptimmune Inc.（一家私人控股公司，开发用于治疗自身免疫性疾病的免疫疗法）董事长。2002年1月至2004年11月，他还担任Peptimmune的总裁。从1991年11月到2000年12月与我们合并，他曾担任Geltex Pharmaceuticals公司（他于1991年共同创立的公司）的主席，在那里他曾担任总裁兼首席执行官（直到1993年5月）。他也曾共同创立Vactex Inc.，并担任其总裁兼首席执行官（从1995年11月到1998年4月被Aquila Biopharmaceuticals，Inc.收购）。Carpenter先生是Integrated Genetics，Inc.的董事会主席，总裁兼首席执行官，该公司是一家生物技术公司，于1989年与我们合并。合并后，直到1991年，他一直担任我们的执行Vice President，以及IG Laboratories，Inc.（一家附属公司，于1995年9月与我们合并）的首席执行官兼董事会主席。Carpenter先生是Hydra Biosciences，Inc.的董事长，该公司开发基于最近发现的离子通道的药物。他也是the Immune Disease Institute的受托人，这是隶属于波士顿Children’s Hospital的非营利机构，从事免疫学研究。
Robert J. Carpenter,has served on Immuneering Corporation Board of Directors since May 2009. Mr. Carpenter also currently serves as the Chairman of Hydra Biosciences LLC, or Hydra Biosciences, a privately held clinical-stage biopharmaceutical company. From 1992 until 2015, he served as the Chief Executive Officer of Boston Medical Investors, Inc., a venture capital firm. Mr. Carpenter has founded and served in executive management and board roles at numerous biotechnology companies, including Olaris Inc., Integrated Genetics and GelTex Pharmaceuticals, both of which merged with Genzyme Corporation, and VacTex Corp., which was acquired by Aquila Biopharmaceuticals, Inc. Mr. Carpenter received his B.S. in engineering from the U.S. Military Academy at West Point, his M.S. in computer science from Stanford University and his M.B.A. from Harvard Business School. - RobertJ.Carpenter Carpenter先生是Boston Medical Investors，Inc.的总裁。Boston Medical Investors，Inc.是他于1994年成立的一家私人控股公司，投资于早期医疗保健公司。Carpenter从2002年1月到2007年8月担任Peptimmune Inc.（一家私人控股公司，开发用于治疗自身免疫性疾病的免疫疗法）董事长。2002年1月至2004年11月，他还担任Peptimmune的总裁。从1991年11月到2000年12月与我们合并，他曾担任Geltex Pharmaceuticals公司（他于1991年共同创立的公司）的主席，在那里他曾担任总裁兼首席执行官（直到1993年5月）。他也曾共同创立Vactex Inc.，并担任其总裁兼首席执行官（从1995年11月到1998年4月被Aquila Biopharmaceuticals，Inc.收购）。Carpenter先生是Integrated Genetics，Inc.的董事会主席，总裁兼首席执行官，该公司是一家生物技术公司，于1989年与我们合并。合并后，直到1991年，他一直担任我们的执行Vice President，以及IG Laboratories，Inc.（一家附属公司，于1995年9月与我们合并）的首席执行官兼董事会主席。Carpenter先生是Hydra Biosciences，Inc.的董事长，该公司开发基于最近发现的离子通道的药物。他也是the Immune Disease Institute的受托人，这是隶属于波士顿Children’s Hospital的非营利机构，从事免疫学研究。
- Robert J. Carpenter,has served on Immuneering Corporation Board of Directors since May 2009. Mr. Carpenter also currently serves as the Chairman of Hydra Biosciences LLC, or Hydra Biosciences, a privately held clinical-stage biopharmaceutical company. From 1992 until 2015, he served as the Chief Executive Officer of Boston Medical Investors, Inc., a venture capital firm. Mr. Carpenter has founded and served in executive management and board roles at numerous biotechnology companies, including Olaris Inc., Integrated Genetics and GelTex Pharmaceuticals, both of which merged with Genzyme Corporation, and VacTex Corp., which was acquired by Aquila Biopharmaceuticals, Inc. Mr. Carpenter received his B.S. in engineering from the U.S. Military Academy at West Point, his M.S. in computer science from Stanford University and his M.B.A. from Harvard Business School.
- Ann E. Berman
-
Ann E. Berman从2006年1月开始担任公司的董事。她担任审计委员会的主席，并担任公司董事会下属的薪酬与提名和治理委员会的委员。从2006年4月到2009年6月，Berman女士担任哈佛大学高级顾问，并从2002年10月到2006年4月担任哈佛大学财务部副总裁兼首席财务官。Berman女士还从2006年开始担任美国洛斯保险公司（Loews Corporation）的董事，并从2011年3月开始担任卡特尔医疗公司（Cantel Medical Corp.）的董事。
Ann E. Berman,Retired advisor to the President of Harvard University. Ms. Berman is also the Chair of the Board of Immuneering Corporation. Ms. Berman was a director of Renalytix plc from 2021 until 2022, Cantel Medical Corp. from 2011 until 2021 and Eaton Vance Corporation from 2006 until 2021. - Ann E. Berman从2006年1月开始担任公司的董事。她担任审计委员会的主席，并担任公司董事会下属的薪酬与提名和治理委员会的委员。从2006年4月到2009年6月，Berman女士担任哈佛大学高级顾问，并从2002年10月到2006年4月担任哈佛大学财务部副总裁兼首席财务官。Berman女士还从2006年开始担任美国洛斯保险公司（Loews Corporation）的董事，并从2011年3月开始担任卡特尔医疗公司（Cantel Medical Corp.）的董事。
- Ann E. Berman,Retired advisor to the President of Harvard University. Ms. Berman is also the Chair of the Board of Immuneering Corporation. Ms. Berman was a director of Renalytix plc from 2021 until 2022, Cantel Medical Corp. from 2011 until 2021 and Eaton Vance Corporation from 2006 until 2021.
高管简历
中英对照 | 中文 | 英文- Benjamin J. Zeskind
Benjamin J.Zeskind自2008年2月起担任我们的联合创始人、总裁、首席执行官和董事会成员。泽斯金德博士在麻省理工学院（MIT）获得电气工程和计算机科学学士学位，生物工程博士学位，在哈佛商学院（Harvard Business School）获得工商管理硕士学位，在那里他被公认为贝克学者，这是最高荣誉奖项。
Benjamin J. Zeskind,has served as Immuneering Corporation Co-Founder, President, Chief Executive Officer and a member of Immuneering Corporation Board of Directors since February 2008. Dr. Zeskind received his S.B. in electrical engineering and computer science and his Ph.D. in bioengineering from Massachusetts Institute of Technology, or MIT, and his M.B.A. from Harvard Business School, where he was recognized as a Baker Scholar, the highest award for distinction.- Benjamin J.Zeskind自2008年2月起担任我们的联合创始人、总裁、首席执行官和董事会成员。泽斯金德博士在麻省理工学院（MIT）获得电气工程和计算机科学学士学位，生物工程博士学位，在哈佛商学院（Harvard Business School）获得工商管理硕士学位，在那里他被公认为贝克学者，这是最高荣誉奖项。
- Benjamin J. Zeskind,has served as Immuneering Corporation Co-Founder, President, Chief Executive Officer and a member of Immuneering Corporation Board of Directors since February 2008. Dr. Zeskind received his S.B. in electrical engineering and computer science and his Ph.D. in bioengineering from Massachusetts Institute of Technology, or MIT, and his M.B.A. from Harvard Business School, where he was recognized as a Baker Scholar, the highest award for distinction.
- Scott Barrett
Scott Barrett自2019年11月起担任我们的首席医疗官。加入我们之前，2016年6月至2019年11月，Barrett博士担任Incyte Corp的全球医疗事务执行董事，Incyte Corp是一家上市生物制药公司，专注于肿瘤和其他感兴趣领域的专有疗法的发现、开发和商业化。在此之前，他从2014年7月到2016年6月担任InfinityPharmaceuticals，Inc.（上市生物制药药物开发公司）的临床开发高级总监。Barrett博士是一名训练有素的医生-科学家，成功的医学肿瘤医生和药物发现和开发专家，拥有30多年的临床和研究经验。他作为受益的霍德森奖学金获得者在约翰霍普金斯大学获得自然科学学士学位，在迈阿密大学医学院获得医学博士学位，并在明尼苏达州罗切斯特的梅奥诊所完成了内科住院医师。巴雷特随后在纪念斯隆-凯特琳癌症中心完成了医学肿瘤学奖学金，并获得了内科和医学肿瘤学的董事会认证。
Scott Barrett,has served as Immuneering Corporation Chief Medical Officer since November 2019. Prior to joining Immuneering Corporation , Dr. Barrett served as the Executive Director of Global Medical Affairs of Incyte Corp, a publicly traded biopharmaceutical company focused on discovery, development and commercialization of proprietary therapeutics in oncology and other areas of interest, from June 2016 until November 2019. Prior to that, he served as the Senior Director of Clinical Development of Infinity Pharmaceuticals, Inc., a publicly traded biopharmaceutical drug development company, from July 2014 until June 2016. Dr. Barrett is a trained physician-scientist, accomplished medical oncologist and a drug discovery and development expert with more than 30 years of clinical and research experience. He received his B.A. in natural science from The Johns Hopkins University as a Beneficial-Hodson Scholarship recipient and his M.D. from the University of Miami. Subsequently, he became double-boarded in Internal Medicine and Medical Oncology, after having completed an internal medicine residency at the Mayo Clinic and his medical oncology fellowship at the Memorial Sloan Kettering Cancer Center.- Scott Barrett自2019年11月起担任我们的首席医疗官。加入我们之前，2016年6月至2019年11月，Barrett博士担任Incyte Corp的全球医疗事务执行董事，Incyte Corp是一家上市生物制药公司，专注于肿瘤和其他感兴趣领域的专有疗法的发现、开发和商业化。在此之前，他从2014年7月到2016年6月担任InfinityPharmaceuticals，Inc.（上市生物制药药物开发公司）的临床开发高级总监。Barrett博士是一名训练有素的医生-科学家，成功的医学肿瘤医生和药物发现和开发专家，拥有30多年的临床和研究经验。他作为受益的霍德森奖学金获得者在约翰霍普金斯大学获得自然科学学士学位，在迈阿密大学医学院获得医学博士学位，并在明尼苏达州罗切斯特的梅奥诊所完成了内科住院医师。巴雷特随后在纪念斯隆-凯特琳癌症中心完成了医学肿瘤学奖学金，并获得了内科和医学肿瘤学的董事会认证。
- Scott Barrett,has served as Immuneering Corporation Chief Medical Officer since November 2019. Prior to joining Immuneering Corporation , Dr. Barrett served as the Executive Director of Global Medical Affairs of Incyte Corp, a publicly traded biopharmaceutical company focused on discovery, development and commercialization of proprietary therapeutics in oncology and other areas of interest, from June 2016 until November 2019. Prior to that, he served as the Senior Director of Clinical Development of Infinity Pharmaceuticals, Inc., a publicly traded biopharmaceutical drug development company, from July 2014 until June 2016. Dr. Barrett is a trained physician-scientist, accomplished medical oncologist and a drug discovery and development expert with more than 30 years of clinical and research experience. He received his B.A. in natural science from The Johns Hopkins University as a Beneficial-Hodson Scholarship recipient and his M.D. from the University of Miami. Subsequently, he became double-boarded in Internal Medicine and Medical Oncology, after having completed an internal medicine residency at the Mayo Clinic and his medical oncology fellowship at the Memorial Sloan Kettering Cancer Center.
- Brett Hall
Brett Hall自2019年11月起担任我们的首席科学官。他还担任BioArkive，Inc.（私人持有的生物技术服务公司BioArkive）的总裁、创始人兼董事会主席，以及Trans Medical Sciences，LLC（私人持有的生物技术和生物制药公司的咨询公司）的总裁兼创始人。在加入我们之前，Hall博士从2015年7月到2018年5月担任Asellus Therapeutics，LLC（一家私人生物技术公司）的首席执行官。从2008年11月到2014年7月，霍尔博士在强生公司担任越来越多的职务，该公司是一家跨国企业，开发医疗设备、药品和消费者包装商品，他最终担任血液病地区据点的生物标志物负责人，他领导了Sylvant和Imbruvica的临床开发转化工作。随后，他从2014年7月到2015年7月担任Medimmune，LLC（阿斯利康制药公司（AstraZeneca Pharmaceuticals LP）的生物制剂部门）的肿瘤转化医学主管，之后过渡到生物技术的执行发现角色。他拥有广泛的药物开发和领导经验，从早期药物发现到转化临床科学，包括多个药物注册。Hall博士在TME和转化科学领域有广泛的发表，并拥有药物药理学和发现的多项专利。他也是俄亥俄州立大学（Ohio State University）的终身助理教授，在那里他的实验室专注于开发人类TME对准模型，以更好地将临床前数据转化为临床，并发现新的生物标志物。在霍尔博士的生命科学职业生涯之前，他曾在美国空军服役，并担任投资银行家。霍尔博士在俄亥俄州立大学获得生物化学学士学位，在西弗吉尼亚大学获得免疫学和癌症生物学博士学位，并在圣犹大儿童研究医院完成了癌细胞表观遗传学博士后研究。
Brett Hall,has served as Immuneering Corporation Chief Scientific Officer since November 2019. He also served as the Founder and Chairman of the board of directors of BioArkive, Inc., or BioArkive, a privately held biotechnology services company from January 2019 until December 2021. Prior to joining Immuneering Corporation , Dr. Hall served as the Chief Executive Officer of Asellus Therapeutics, LLC, a privately held biotechnology company, from July 2015 until May 2018. Dr. Hall served in roles of increasing responsibility with Johnson & Johnson, a multinational corporation that develops medical devices, pharmaceuticals and consumer packaged goods, from November 2008 until July 2014, culminating in his role as the Head of Biomarkers of the Hematologic Disease Area Stronghold, where he led translational efforts for Sylvant and Imbruvica through clinical development. Subsequently, he served as the Head of Translational Medicine of Oncology at Medimmune, LLC, the biologics division of AstraZeneca Pharmaceuticals LP, from July 2014 until July 2015, before transitioning to executive discovery roles in biotechnology. He has extensive drug development and leadership experience ranging from early drug discovery through translational clinical sciences, including multiple drug registrations. Dr. Hall has extensively published in the areas of tumor microenvironment (TME) and translational sciences, and holds multiple patents for drug pharmacology and discovery. He was also a tenure-track Assistant Professor at Ohio State University where his laboratory focused on the development of human TME-aligned models to better translate preclinical data into the clinic and discover novel biomarkers. Prior to Dr. Hall's career in life sciences, he served in the United States Air Force and worked as an investment banker. Dr. Hall received his B.S. in biochemistry from Ohio State University, his Ph.D. in immunology and cancer biology from West Virginia University and completed his post-doctoral fellowship in cancer cell epigenetics at St. Jude Children's Research Hospital.- Brett Hall自2019年11月起担任我们的首席科学官。他还担任BioArkive，Inc.（私人持有的生物技术服务公司BioArkive）的总裁、创始人兼董事会主席，以及Trans Medical Sciences，LLC（私人持有的生物技术和生物制药公司的咨询公司）的总裁兼创始人。在加入我们之前，Hall博士从2015年7月到2018年5月担任Asellus Therapeutics，LLC（一家私人生物技术公司）的首席执行官。从2008年11月到2014年7月，霍尔博士在强生公司担任越来越多的职务，该公司是一家跨国企业，开发医疗设备、药品和消费者包装商品，他最终担任血液病地区据点的生物标志物负责人，他领导了Sylvant和Imbruvica的临床开发转化工作。随后，他从2014年7月到2015年7月担任Medimmune，LLC（阿斯利康制药公司（AstraZeneca Pharmaceuticals LP）的生物制剂部门）的肿瘤转化医学主管，之后过渡到生物技术的执行发现角色。他拥有广泛的药物开发和领导经验，从早期药物发现到转化临床科学，包括多个药物注册。Hall博士在TME和转化科学领域有广泛的发表，并拥有药物药理学和发现的多项专利。他也是俄亥俄州立大学（Ohio State University）的终身助理教授，在那里他的实验室专注于开发人类TME对准模型，以更好地将临床前数据转化为临床，并发现新的生物标志物。在霍尔博士的生命科学职业生涯之前，他曾在美国空军服役，并担任投资银行家。霍尔博士在俄亥俄州立大学获得生物化学学士学位，在西弗吉尼亚大学获得免疫学和癌症生物学博士学位，并在圣犹大儿童研究医院完成了癌细胞表观遗传学博士后研究。
- Brett Hall,has served as Immuneering Corporation Chief Scientific Officer since November 2019. He also served as the Founder and Chairman of the board of directors of BioArkive, Inc., or BioArkive, a privately held biotechnology services company from January 2019 until December 2021. Prior to joining Immuneering Corporation , Dr. Hall served as the Chief Executive Officer of Asellus Therapeutics, LLC, a privately held biotechnology company, from July 2015 until May 2018. Dr. Hall served in roles of increasing responsibility with Johnson & Johnson, a multinational corporation that develops medical devices, pharmaceuticals and consumer packaged goods, from November 2008 until July 2014, culminating in his role as the Head of Biomarkers of the Hematologic Disease Area Stronghold, where he led translational efforts for Sylvant and Imbruvica through clinical development. Subsequently, he served as the Head of Translational Medicine of Oncology at Medimmune, LLC, the biologics division of AstraZeneca Pharmaceuticals LP, from July 2014 until July 2015, before transitioning to executive discovery roles in biotechnology. He has extensive drug development and leadership experience ranging from early drug discovery through translational clinical sciences, including multiple drug registrations. Dr. Hall has extensively published in the areas of tumor microenvironment (TME) and translational sciences, and holds multiple patents for drug pharmacology and discovery. He was also a tenure-track Assistant Professor at Ohio State University where his laboratory focused on the development of human TME-aligned models to better translate preclinical data into the clinic and discover novel biomarkers. Prior to Dr. Hall's career in life sciences, he served in the United States Air Force and worked as an investment banker. Dr. Hall received his B.S. in biochemistry from Ohio State University, his Ph.D. in immunology and cancer biology from West Virginia University and completed his post-doctoral fellowship in cancer cell epigenetics at St. Jude Children's Research Hospital.
- Michael D. Bookman
Michael D.Bookman自2021年7月起担任我们的总法律顾问兼秘书。在加入我们之前，Bookman先生从2021年1月到2021年7月担任FrequencyTherapeutics，Inc.或Frequency的总法律顾问兼秘书，从2019年9月到2021年1月担任Frequency的副总法律顾问兼秘书。在担任Frequency的职位之前，他曾担任Latham&Watkins LLP的合伙人，Latham&Watkins LLP是一家领先的国际律师事务所，在那里他曾从事公司交易、证券、一般业务和治理事务，重点是代表高增长的技术和生命科学公司，从2012年10月到2019年8月。他目前是波士顿律师协会生命科学咨询委员会的成员。Bookman先生在迈阿密大学以优异成绩获得金融学士学位，在弗吉尼亚大学法学院获得法学博士学位。
Michael D. Bookman,has served as Immuneering Corporation Chief Legal Officer and Secretary since January 2023 and General Counsel and Secretary from July 2021 to January 2023. Prior to joining Immuneering Corporation , Mr. Bookman served as the General Counsel and Secretary of Frequency Therapeutics, Inc., or Frequency, from January 2021 until July 2021, and the Deputy General Counsel and Secretary of Frequency from September 2019 until January 2021. Prior to Mr. Bookman's role at Frequency, he was an associate at Latham & Watkins LLP, a leading international law firm where he worked on corporate transactional, securities and general business and governance matters, with an emphasis on representing high-growth technology and life sciences companies, from October 2012 until August 2019. Mr. Bookman received his B.B.A., summa cum laude, in finance from the University of Miami and his J.D. from the University of Virginia School of Law.- Michael D.Bookman自2021年7月起担任我们的总法律顾问兼秘书。在加入我们之前，Bookman先生从2021年1月到2021年7月担任FrequencyTherapeutics，Inc.或Frequency的总法律顾问兼秘书，从2019年9月到2021年1月担任Frequency的副总法律顾问兼秘书。在担任Frequency的职位之前，他曾担任Latham&Watkins LLP的合伙人，Latham&Watkins LLP是一家领先的国际律师事务所，在那里他曾从事公司交易、证券、一般业务和治理事务，重点是代表高增长的技术和生命科学公司，从2012年10月到2019年8月。他目前是波士顿律师协会生命科学咨询委员会的成员。Bookman先生在迈阿密大学以优异成绩获得金融学士学位，在弗吉尼亚大学法学院获得法学博士学位。
- Michael D. Bookman,has served as Immuneering Corporation Chief Legal Officer and Secretary since January 2023 and General Counsel and Secretary from July 2021 to January 2023. Prior to joining Immuneering Corporation , Mr. Bookman served as the General Counsel and Secretary of Frequency Therapeutics, Inc., or Frequency, from January 2021 until July 2021, and the Deputy General Counsel and Secretary of Frequency from September 2019 until January 2021. Prior to Mr. Bookman's role at Frequency, he was an associate at Latham & Watkins LLP, a leading international law firm where he worked on corporate transactional, securities and general business and governance matters, with an emphasis on representing high-growth technology and life sciences companies, from October 2012 until August 2019. Mr. Bookman received his B.B.A., summa cum laude, in finance from the University of Miami and his J.D. from the University of Virginia School of Law.
- Harold E. Brakewood
Harold E. Brakewood，自2023年3月起担任Immuneering Corporation首席商务官。在加入Immuneering之前，Brakewood先生于2015年12月至2021年12月受雇于再生元制药，最近一次担任副总裁兼肿瘤学、新冠病毒和新产品规划业务部门负责人。他于1989年至1992年受雇于默沙东公司，并于1994年至2015年再次担任各种责任越来越大的商业职务，包括战略规划、业务发展、品牌管理和一家肿瘤学初创企业。他拥有哈佛商学院的工商管理硕士学位、达特茅斯大学的物理学硕士学位和鲍登学院的A.B.学位。
Harold E. Brakewood,has served as Immuneering Corporation Chief Business Officer since March 2023. Prior to Immuneering, Mr. Brakewood was employed by Regeneron Pharmaceuticals from December 2015 to December 2021 most recently as Vice President and head of a business unit for oncology, covid19, and new product planning. He was employed by Merck & Company, Inc. from 1989 to 1992, and again from 1994 to 2015 in a variety of commercial roles of increasing responsibility including strategic planning, business development, brand management and an oncology start-up venture. He holds an M.B.A. from Harvard Business School, an M.A. in physics from Dartmouth, and an A.B. from Bowdoin College.- Harold E. Brakewood，自2023年3月起担任Immuneering Corporation首席商务官。在加入Immuneering之前，Brakewood先生于2015年12月至2021年12月受雇于再生元制药，最近一次担任副总裁兼肿瘤学、新冠病毒和新产品规划业务部门负责人。他于1989年至1992年受雇于默沙东公司，并于1994年至2015年再次担任各种责任越来越大的商业职务，包括战略规划、业务发展、品牌管理和一家肿瘤学初创企业。他拥有哈佛商学院的工商管理硕士学位、达特茅斯大学的物理学硕士学位和鲍登学院的A.B.学位。
- Harold E. Brakewood,has served as Immuneering Corporation Chief Business Officer since March 2023. Prior to Immuneering, Mr. Brakewood was employed by Regeneron Pharmaceuticals from December 2015 to December 2021 most recently as Vice President and head of a business unit for oncology, covid19, and new product planning. He was employed by Merck & Company, Inc. from 1989 to 1992, and again from 1994 to 2015 in a variety of commercial roles of increasing responsibility including strategic planning, business development, brand management and an oncology start-up venture. He holds an M.B.A. from Harvard Business School, an M.A. in physics from Dartmouth, and an A.B. from Bowdoin College.
- Mallory Morales
Mallory Morales，自2021年5月起担任Immuneering Corporation财务副总裁，自2022年8月起担任副总裁、财务和财务主管。在加入Immuneering Corporation之前，Morales女士于2020年10月至2021年5月期间在生物制药公司吉利德科学公司（“吉利德”）担任战略金融业务合伙人，负责监督Immunomedics, Inc.（“Immunomedics”）的研发组织在2020年10月被吉利德收购后的整合工作。2018年4月至2020年10月，她在抗体药物偶联公司Immunomedics担任董事兼助理财务总监，负责监督年度运营预算、预测和业务规划。从2014年5月到2018年4月，莫拉莱斯女士在个人护理公司L'Or é al S.A.（“欧莱雅”）担任资历不断增加的职务，最近担任欧莱雅专业产品部门财务总监和全球品牌总监，负责监督和管理所有财务和会计职能。莫拉莱斯女士是一名注册会计师，她的职业生涯始于普华永道会计师事务所的审计师。她以优异的成绩从奥尔巴尼的纽约州立大学获得了会计和商业学士学位。
Mallory Morales,has served as Immuneering Corporation Vice President, Finance since May 2021 and as Vice President, Finance and Treasurer since August 2022. Prior to joining Immuneering Corporation , Ms. Morales served as Strategic Finance Business Partner at Gilead Sciences, Inc. ("Gilead"), a biopharmaceutical company, from October 2020 to May 2021, where she oversaw the integration of the research and development organization of Immunomedics, Inc. ("Immunomedics") following its acquisition by Gilead in October 2020. From April 2018 to October 2020, she served as Director and Assistant Controller at Immunomedics, an antibody drug conjugate company, where she oversaw the annual operating budget, forecasting and business planning. From May 2014 to April 2018, Ms. Morales held roles of increasing seniority at L'Oréal S.A. ("L'Oréal"), a personal care company, most recently as Director of Finance and Global Brand Controller, L'Oreal Professional Products Division, where she oversaw and managed all financial and accounting functions. Ms. Morales is a CPA and began her career as an auditor for Pricewaterhouse Coopers. She earned her B.S. in Accounting and Business with honors from the State University of New York at Albany.- Mallory Morales，自2021年5月起担任Immuneering Corporation财务副总裁，自2022年8月起担任副总裁、财务和财务主管。在加入Immuneering Corporation之前，Morales女士于2020年10月至2021年5月期间在生物制药公司吉利德科学公司（“吉利德”）担任战略金融业务合伙人，负责监督Immunomedics, Inc.（“Immunomedics”）的研发组织在2020年10月被吉利德收购后的整合工作。2018年4月至2020年10月，她在抗体药物偶联公司Immunomedics担任董事兼助理财务总监，负责监督年度运营预算、预测和业务规划。从2014年5月到2018年4月，莫拉莱斯女士在个人护理公司L'Or é al S.A.（“欧莱雅”）担任资历不断增加的职务，最近担任欧莱雅专业产品部门财务总监和全球品牌总监，负责监督和管理所有财务和会计职能。莫拉莱斯女士是一名注册会计师，她的职业生涯始于普华永道会计师事务所的审计师。她以优异的成绩从奥尔巴尼的纽约州立大学获得了会计和商业学士学位。
- Mallory Morales,has served as Immuneering Corporation Vice President, Finance since May 2021 and as Vice President, Finance and Treasurer since August 2022. Prior to joining Immuneering Corporation , Ms. Morales served as Strategic Finance Business Partner at Gilead Sciences, Inc. ("Gilead"), a biopharmaceutical company, from October 2020 to May 2021, where she oversaw the integration of the research and development organization of Immunomedics, Inc. ("Immunomedics") following its acquisition by Gilead in October 2020. From April 2018 to October 2020, she served as Director and Assistant Controller at Immunomedics, an antibody drug conjugate company, where she oversaw the annual operating budget, forecasting and business planning. From May 2014 to April 2018, Ms. Morales held roles of increasing seniority at L'Oréal S.A. ("L'Oréal"), a personal care company, most recently as Director of Finance and Global Brand Controller, L'Oreal Professional Products Division, where she oversaw and managed all financial and accounting functions. Ms. Morales is a CPA and began her career as an auditor for Pricewaterhouse Coopers. She earned her B.S. in Accounting and Business with honors from the State University of New York at Albany.
- Leah R. Neufeld
Leah R. Neufeld，自2022年10月起担任Immuneering Corporation首席人事官。Neufeld女士从Luzsana Biotechnology加入Immuneering Corporation，自2021年8月起担任首席人力资源官，并作为执行团队的一员，帮助在全球范围内建立了Luzsana，作为中国最大的制药公司恒瑞医药的子公司。此前，她于2019年起在Prevail Therapeutics担任副总裁，People，此前该公司于2021年被礼来收购。在此之前，从2015年到2019年，Neufeld女士担任Intercept制药的人力资源主管。在此之前的2014年至2015年，她曾担任NPS制药公司的全球人力资源主管，直到2015年该公司被Shire Pharmaceuticals收购。2009年至2014年，她在Daiichi Sankyo Pharma Development担任越来越重要的职务，最近担任人力资源总监。在她职业生涯的早期，从2002年到2009年，她在强生担任过多个人力资源职位，包括消费者事业部及其肿瘤公司Ortho Biotech的人力资源部经理。Neufeld女士获得了美国大学心理学学士学位和约翰霍普金斯大学职业咨询和组织发展硕士学位。
Leah R. Neufeld,has served as Immuneering Corporation Chief People Officer since October 2022. Ms. Neufeld joins Immuneering Corporation from Luzsana Biotechnology, where, since August 2021, she served as Chief Human Resources Officer, and as part of the executive team, helped establish Luzsana globally as a subsidiary of Hengrui Medicines, the largest Pharma company in China. Previously, she was the Vice President, People, at Prevail Therapeutics, from 2019 and following its acquisition by Eli Lilly in 2021. Prior to that, from 2015 through 2019, Ms. Neufeld was the Head of Human Resources at Intercept Pharmaceuticals. Before that, from 2014 to 2015, she was the Global Head of Human Resources for NPS Pharma until it was acquired by Shire Pharmaceuticals in 2015. From 2009 to 2014, she held positions of increasing responsibility at Daiichi Sankyo Pharma Development, most recently serving as Director of Human Resources. Earlier in her career, from 2002 to 2009, she held various human resources positions at Johnson & Johnson, including Manager of Human Resources in the consumer division and its oncology company called Ortho Biotech. Ms. Neufeld earned a B.A. in psychology from the American University and an M.S. in career counseling and organization development from Johns Hopkins University.- Leah R. Neufeld，自2022年10月起担任Immuneering Corporation首席人事官。Neufeld女士从Luzsana Biotechnology加入Immuneering Corporation，自2021年8月起担任首席人力资源官，并作为执行团队的一员，帮助在全球范围内建立了Luzsana，作为中国最大的制药公司恒瑞医药的子公司。此前，她于2019年起在Prevail Therapeutics担任副总裁，People，此前该公司于2021年被礼来收购。在此之前，从2015年到2019年，Neufeld女士担任Intercept制药的人力资源主管。在此之前的2014年至2015年，她曾担任NPS制药公司的全球人力资源主管，直到2015年该公司被Shire Pharmaceuticals收购。2009年至2014年，她在Daiichi Sankyo Pharma Development担任越来越重要的职务，最近担任人力资源总监。在她职业生涯的早期，从2002年到2009年，她在强生担任过多个人力资源职位，包括消费者事业部及其肿瘤公司Ortho Biotech的人力资源部经理。Neufeld女士获得了美国大学心理学学士学位和约翰霍普金斯大学职业咨询和组织发展硕士学位。
- Leah R. Neufeld,has served as Immuneering Corporation Chief People Officer since October 2022. Ms. Neufeld joins Immuneering Corporation from Luzsana Biotechnology, where, since August 2021, she served as Chief Human Resources Officer, and as part of the executive team, helped establish Luzsana globally as a subsidiary of Hengrui Medicines, the largest Pharma company in China. Previously, she was the Vice President, People, at Prevail Therapeutics, from 2019 and following its acquisition by Eli Lilly in 2021. Prior to that, from 2015 through 2019, Ms. Neufeld was the Head of Human Resources at Intercept Pharmaceuticals. Before that, from 2014 to 2015, she was the Global Head of Human Resources for NPS Pharma until it was acquired by Shire Pharmaceuticals in 2015. From 2009 to 2014, she held positions of increasing responsibility at Daiichi Sankyo Pharma Development, most recently serving as Director of Human Resources. Earlier in her career, from 2002 to 2009, she held various human resources positions at Johnson & Johnson, including Manager of Human Resources in the consumer division and its oncology company called Ortho Biotech. Ms. Neufeld earned a B.A. in psychology from the American University and an M.S. in career counseling and organization development from Johns Hopkins University.